Trial Profile
Combination of Erlotonib plus Sorafenib in Patients with unresectable Hepatocellular Carcinoma; a randomized placebo controlled Phase II pilot trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms Erlosora-1
- 13 Jan 2018 Status changed from recruiting to discontinued.
- 26 Jul 2011 New trial record